Duloxetine HCL DR Capsules

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2D2-26-D-0008

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

Salcete, Goa, INDIA

SourceSAM
Documents3
The Defense Logistics Agency (DLA) Troop Support, operating under the Department of Defense, has issued an award notice for the procurement of Duloxetine HCL Delayed Release (DR) Capsules. This contract, identified by procurement number SPE2D2-26-D-0008, falls under the NAICS code 325412, which pertains to Pharmaceutical Preparation Manufacturing, and is further classified under Product Service Code 6505, indicating drugs and biologicals. The primary objective of this procurement is to secure a reliable supply of Duloxetine HCL DR Capsules, a pharmaceutical product essential for supporting the health and readiness of defense personnel. The scope of the contract encompasses the manufacturing and delivery of these capsules, with the place of performance specified as Salcete, Goa, India. This location highlights the global sourcing approach of the DLA to ensure access to high-quality pharmaceutical preparations. The intended outcome of this procurement activity is to maintain an uninterrupted supply chain for critical medications, thereby supporting the operational requirements of the Department of Defense. Contractors are expected to adhere to stringent manufacturing standards and regulatory requirements associated with pharmaceutical production, ensuring product efficacy, safety, and compliance with applicable laws. The contracting entity for this award is DLA Troop Support, a federal office within the Defense Logistics Agency. Interested parties or stakeholders seeking further information may contact the primary point of contact, Christopher Newman, at [email protected] or by phone at 445-737-7371. A secondary contact, Jason Wray, is also available at [email protected] or 445-737-6304. This award notice is currently active and was posted on July 14, 2026. Additional details, including attachments related to the award, can be accessed via the official SAM.gov opportunity page at https://sam.gov/opp/4f79f301b75d4d79a2fd7299c78acc29/view. Contractors evaluating this opportunity should note that the procurement is focused on the consistent and compliant manufacturing of Duloxetine HCL DR Capsules, with performance expected in Salcete, Goa, India. The notice does not specify set-aside requirements or special considerations, but compliance with pharmaceutical manufacturing standards and the ability to deliver to the specified location are essential. This opportunity is well-suited for organizations with established capabilities in pharmaceutical preparation manufacturing and experience in supporting large-scale, mission-critical government contracts.